Search

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Focus on Alliance Management

Consumer Health Data Privacy

This Consumer Health Data Privacy Policy applies to “Consumer Health Data,” as that term has been defined under applicable law.

CIA Reporting Requirements

Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US

Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Protein Degraders: Changing the Game in Cancer Drug Discovery

Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

SPEVIGO approved for expanded indications in China and the US

FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Why role models matter for black veterinarians: One doctor's story

Fighting Rabies in Madagascar | Boehringer Ingelheim US

Find out more about the Boehringer Ingelheim efforts to fight Rabies in Madagascar. Hear from a veterinarian who administered 75,000 vaccines to cats & dogs on the island.

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Xochimilco

With its presence in Greece of more than a half century,

Growing fresh produce for a cause at our U.S. headquarters

Social Impact | COVID-19 | Boehringer Ingelheim US

Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.

Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.

She finds purpose in the saddle and pursues a passion for horses – at home and work

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

Recognized as an inclusive workplace for the fifth time

Recognized as an Inclusive Workplace for the Fifth Time

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.

Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

Cafeteria Crews Cook for Community | Boehringer Ingelheim US

Read more on how BI cafeteria crews are supporting their communities by cooking over 500 meals a day for first responders & others during the pandemic.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers